APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
MOMA Therapeutics
University of California, San Francisco
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Qilu Pharmaceutical Co., Ltd.
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nuvation Bio Inc.
Cambridge University Hospitals NHS Foundation Trust
Exelixis
AstraZeneca
Australasian Gastro-Intestinal Trials Group
University of Colorado, Denver
Georgetown University
Asan Medical Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Tango Therapeutics, Inc.
University Health Network, Toronto
Azienda Ospedaliero-Universitaria di Modena
Seoul National University Hospital
Seoul National University Hospital
AstraZeneca
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Academic and Community Cancer Research United
AstraZeneca
Yale University
Canadian Cancer Trials Group
AstraZeneca
Ellipses Pharma
Sheba Medical Center
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca
Royal Marsden NHS Foundation Trust
AstraZeneca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
The Christie NHS Foundation Trust